ProfileGDS5678 / 1454678_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 94% 94% 92% 92% 90% 90% 86% 87% 91% 92% 90% 91% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1763594
GSM967853U87-EV human glioblastoma xenograft - Control 28.2565794
GSM967854U87-EV human glioblastoma xenograft - Control 38.3366994
GSM967855U87-EV human glioblastoma xenograft - Control 47.8951592
GSM967856U87-EV human glioblastoma xenograft - Control 57.6187492
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9569390
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0187490
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4808786
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6478387
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5382491
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6271392
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3393490
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3230191
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9215493